Status and phase
Conditions
Treatments
About
Null hypothesis: There is no difference in the efficacy of IVPR and EPR during an episode of hypokalemia.
Alternate Hypothesis: There is a mean difference of 15% in Serum Potassium levels between the two groups.
Objective: To compare the efficacy EPR and IVPR for treatment of hypokalemia (measured as change in serum potassium levels in milliequivalent/L after potassium replacement)
Full description
Hypokalemia is frequently encountered in daily clinical practices of cardiac intensive care unit (CICU). The development of ventricular arrhythmias related to hypokalemia can lead to sudden cardiac death. Thus, potassium replacement therapy is the cornerstone therapy for hypokalemia.Though intravenous potassium replacement (IVPR) in hypokalemia is the preferred route in most intensive care settings, it is associated with known safety risks. Inappropriately administered, IVPR can lead to arrhythmias, cardiac arrest and death 1, 7, 8. Given these risks, IVPR is considered a "high-alert medication" by Institute of Safe Medication practice.
Enteral potassium replacement (EPR), with its superior safety profile may be a better alternative to IVPR. A retrospective review showed that the efficacy of EPR was comparable to IVPR in pediatric patients after congenital heart disease.
The investigators seek to explore this comparison between EPR and IVPR in a randomized prospective trial
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
• All patients undergoing surgical repair/palliation of congenital heart lesion at the Aga Khan University Hospital and admitted to the pediatric cardiac intensive care unit (PCICU) for post-operative management.
Exclusion criteria
• Patients with acute renal failure (estimated clearance creatinine - eccr <50)
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups
Loading...
Central trial contact
Anwar Ul Haque, MD; Babar S Hasan, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal